Abcam, ab315379, Anti-ASIC2 antibody [EPR25412-63] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal ASIC2 antibody. Carrier free. Suitable for WB, IP and reacts with Human, Mouse, Rat, Transfected cell lysate - Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR25412-63,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human, Mouse, Rat,
Applications:IP, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab315379 is the carrier-free version of
ab315378
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ASIC2 also known as amiloride-sensitive cation channel 2 or ACCN1 is a protein involved in ion transport. It forms part of the acid-sensing ion channel (ASIC) family and functions as a voltage-insensitive proton-gated ion channel. ASIC2 is known to have a mass of approximately 60 kDa. Expression is mainly noted in the central nervous system particularly in neurons as well as in other tissues such as the heart and lungs.
Biological function summary
ASIC2 contributes to the detection and response to changes in extracellular pH playing a role in processes such as pain perception and synaptic plasticity. ASIC2 can form homo- or heteromeric complexes with other ASIC proteins influencing the channel properties like ion selectivity and gating. By participating in these complexes ASIC2 affects neuronal signaling and potentially mood regulation in the central nervous system.
Pathways
ASIC2 plays a role in the proton-activated pathways by influencing neuronal excitability. One key pathway includes the pain transduction pathway where ASIC2 in combination with other ASIC family members like ASIC1 and ASIC3 helps mediate pain sensation in response to acids. This regulation is important for maintaining normal sensory functions and could be linked with synaptic functions and neurodegenerative processes.
ASIC2 relates to conditions such as ischemic brain injury and anxiety disorders. During ischemic events ASIC2 contributes to neuronal death making it a target for potential therapeutic interventions. In anxiety disorders alterations in ASIC2 expression or function could impact mood regulation. The protein interacts with other proteins like ASIC1 in these disorder-related pathways suggesting that modulating ASIC interactions might offer a strategy for therapeutic developments.